It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Besides the standard parameters used for colorectal cancer (CRC) management, new features are needed in clinical practice to improve progression-free and overall survival. In some cancers, the microenvironment mechanical properties can contribute to cancer progression and metastasis formation, or constitute a physical barrier for drug penetration or immune cell infiltration. These mechanical properties remain poorly known for colon tissues. Using a multidisciplinary approach including clinical data, physics and geostatistics, we characterized the stiffness of healthy and malignant colon specimens. For this purpose, we analyzed a prospective cohort of 18 patients with untreated colon adenocarcinoma using atomic force microscopy to generate micrometer-scale mechanical maps. We characterized the stiffness of normal epithelium samples taken far away or close to the tumor area and selected tumor tissue areas. These data showed that normal epithelium was softer than tumors. In tumors, stroma areas were stiffer than malignant epithelial cell areas. Among the clinical parameters, tumor left location, higher stage, and RAS mutations were associated with increased tissue stiffness. Thus, in patients with CRC, measuring tumor tissue rigidity may have a translational value and an impact on patient care.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Institut Régional du Cancer Montpellier (ICM), Montpellier, France (GRID:grid.418189.d) (ISNI:0000 0001 2175 1768); Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141); Unité de Recherche Translationnelle, Institut du Cancer de Montpellier (ICM), Montpellier, France (GRID:grid.418189.d) (ISNI:0000 0001 2175 1768)
2 Université de Montpellier, Centre de Biologie Structurale (CBS), CNRS, INSERM, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
3 Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141); Centre Hospitalier Universitaire (CHU) Lapeyronie, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X)
4 Institut Régional du Cancer Montpellier (ICM), Montpellier, France (GRID:grid.418189.d) (ISNI:0000 0001 2175 1768); Unité de Recherche Translationnelle, Institut du Cancer de Montpellier (ICM), Montpellier, France (GRID:grid.418189.d) (ISNI:0000 0001 2175 1768)
5 Institut Régional du Cancer Montpellier (ICM), Montpellier, France (GRID:grid.418189.d) (ISNI:0000 0001 2175 1768); Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
6 Université de Montpellier, ENSCM, Institut des Biomolécules Max Mousseron (IBMM), UMR5247 CNRS, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
7 Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)